ライフサイエンスコーパス: syringe

1 injection of antigen using a 27G needle and syringe.

2 easily controlled by the operator through a syringe.

3 tic filter holders connected to a disposable syringe.

4 k adapter connected to a HTC PAL autosampler syringe.

5 er seven extraction cycles of air pumping by syringe.

6 f a reaction-diffusion front within a 50 muL syringe.

7 ite reactions than was the use of needle and syringe.

8 of water for the calibration of the sampling syringe.

9 e-free jet injector compared with needle and syringe.

10 e to influenza vaccine given with needle and syringe.

11 armaJet, Golden, CO, USA) or with needle and syringe.

12 water extraction using a modified disposable syringe.

13 every 4 weeks until week 48 as a pre-filled syringe.

14 mmation, as it sometimes happens with normal syringe.

15 autosampler equipped with a custom-machined syringe.

16 vice, although not when injected by a needle-syringe.

17 ntravitreal bevacizumab preloaded in insulin syringes.

18 njected in vivo through conventional needled syringes.

19 robes cultured from patients and from unused syringes.

20 s, their location, and whether they sell OTC syringes.

21 g a single vial of bevacizumab into multiple syringes.

22 the majority of patients and from all unused syringes.

23 Pharmacists prepared the syringes.

24 densities of IDUs had limited access to OTC syringes.

25 jections should be supplied in silicone-free syringes.

26 ing in glass vials and injection using glass syringes.

27 with a combination of patency and reflux on syringing.

28 ing and minimal or no reflux on nasolacrimal syringing.

29 mptoms of watering and 50% to 100% reflux on syringing.

30 BD, Franklin Lakes, NJ) 0.3-mL polypropylene syringes, 14.4% of eyes receiving ranibizumab in 1.0-mL

31 ith 306 doses of mRNA (80-640 mug) by needle-syringe (18 intradermally and 24 intramuscularly) or nee

32 elatively high prevalence of sharing needles/syringes (18%-28% in the last injection), the low levels

33 ne syringes or more recently glass prefilled syringes, 48.5% of eyes receiving aflibercept in 1.0-mL

34 In the instrument-free device, a medical syringe (5 mL) prefabricated with a magnet was used for

35 icone oil droplets compared with priming the syringe (6.4% [47 of 739] vs 0.5% [12 of 2627]; Fisher e

36 frequency, encampment closures, and lack of syringe access as promoters of continued HIV transmissio

37 medication-assisted treatment combined with syringe access programs (MAT+).

38 medication-assisted treatment combined with syringe access programs (MAT+).

39 microscopy apparatus, and a set of motorized syringes, all controlled by a computer.

40 r persons who inject drugs (PWIDs) stockpile syringes, an important and novel aspect of NSP coverage.

41 -automated magnetic stirring-assisted lab-in-syringe analytical procedure has been developed for the

42 d glutamic acid, forms a solid-like gel in a syringe and can be shear-thin delivered to the lumen of

43 Higher rates of syringe and equipment sharing and lower prevalence of op

44 evice was compared to delivery by needle and syringe and evaluated for safety and immunogenicity.

45 onstrated by their ability to flow through a syringe and gel at the site of MI in rat models.

46 clinics, prison health services, and needle syringe and oral substitution therapy programs; improvin

47 bly (shear-thinning) when injected through a syringe and then reassemble within seconds (self-healing

48 let severity between BD 1.0-mL polypropylene syringes and controls (P = 1.0).

49 l as HIV-1 infectivity could be abrogated in syringes and filters.

50 herapeutics to the desired injection site by syringes and hollow needles typically depends on the ope

51 ations are conveniently conducted in plastic syringes and in the absence of any additives or external

52 In 2000, reuse of disposable syringes and inadequately sterilized syringes resulted i

53 t was anatomic patency based on nasolacrimal syringing and categorized as (a) fully patent, minimal,

54 patent canalicular system as demonstrated by syringing and probing.

55 fixed-volume capillary, a pre-filled tube, a syringe, and a dropper); this kit would cost $0.50 when

56 -healing behavior, can be injected through a syringe, and rapidly recover their mechanical properties

57 to perforate the host membrane, similar to a syringe, and translocate toxic enzymes into the host cel

58 iving aflibercept in 1.0-mL BD polycarbonate syringes, and 0% of eyes in controls.

59 that use ultrasonics, handpieces, air-water syringes, and lasers generate sprays, a fraction of whic

60 d from 36.8% to 26.0% (P = .007) for sharing syringes, and the proportion of undiagnosed HIV infectio

61 t of rapid, simple, 1-step, room-temperature syringe-and-vial radiolabeling of (68)Ga radiopharmaceut

62 Although pharmacy sales of OTC syringes are associated with reduced injection-mediated

63 IPV was administered by needle-syringe as an intramuscular full dose (0.5 mL), and fIPV

64 ssure regulator, assembly of stainless-steel syringes, assembly of a continuous flow system with mult

65 igned to receive vaccinations via needle and syringe at 0 and 8 weeks, 0 and 12 weeks, 0, 4, and 8 we

66 ula, ratio of synovial enhancement to saline syringe at full dose = 0.337 + 1.070 x ratio of synovial

67 70 x ratio of synovial enhancement to saline syringe at half dose, can be used to convert the normali

68 and trends in sexual behaviors, drug use and syringe availability among PWID were captured through Na

69 We have developed a suite of whole-blood, syringe-based assay systems that can be used to reproduc

70 he logistic obstacles surrounding needle-and-syringe-based immunization as well as to facilitate the

71 transferred to the GC x GC instrument via a syringe-based interface mounted on an autosampler.

72 pylene syringes than BD 1.0-mL polypropylene syringes, BD 1.0-mL polycarbonate syringes, or controls

73 onally, as silicone oil-lubricated prefilled syringes become a favored primary packaging for biothera

74 Priming the syringe before injection was associated with a lower fre

75 From May to November 2016, nonpriming the syringe before the intravitreal injection had a higher r

76 on (AOR=3.05; 95% CI 1.40, 6.66), and recent syringe borrowing (AOR 1.59; 95% CI 1.07, 2.36).

77 version, prevalent HIV infection, and recent syringe borrowing.

78 All 39 countries stopped using sterilizable syringes by 2004.

79 avitreal bevacizumab was prepared in insulin syringes by a compounding pharmacy.

80 onnel, treatments were administered in black syringes by personnel not involved in any study assessme

81 se extraction (D-mu-SPE) based on the lab-in-syringe concept is reported.

82 es that using hematophagous flies as 'flying syringes' constitutes an interesting approach to investi

83 domized to receive injections from identical syringes containing placebo or anakinra subcutaneously o

84 e compounding procedures used to prepare the syringes containing the bevacizumab.

85 rticipants reported higher rates of adequate syringe coverage, linkage to HIV care and OST.

86 ld chain, CTC) and interventions (needle and syringe, CPAD) were modelled across facility or communit

87 way, total injections in the last month, and syringes currently stockpiled in 2014.

88 dvanced type of polymeric hydrogel, that are syringe-deliverable through hypodermic needles.

89 gnment is achieved by the shearing forces of syringe delivery, it is also dependent on the amino acid

90 A sensitive and selective automated in-syringe dispersive liquid-liquid microextraction (DLLME)

91 gh coverage of both NSP and OST (>200 needle-syringes distributed per PWID and >40 OST recipients per

92 low according to WHO indicators (<100 needle-syringes distributed per PWID per year; <20 OST recipien

93 33 (uncertainty interval [UI] 21-50) needle-syringes distributed via NSP per PWID annually, and 16 (

94 e programmes is cost-effective compared with syringe distribution alone, but when combined with linka

95 cessation and "breaks"; (5) scaled-up needle/syringe distribution, HCV treatment, and vaccines, accor

96 of histidinemia was demonstrated by the IEF syringe-ESI-MS system with accuracy from 88.25% to 102.1

97 tion services should be provided (needle and syringe exchange programs, supervised injection, and ava

98 s in harm reduction, including illegality of syringe exchange services.

99 raction efficacy were investigated including syringe fill strokes, syringe pull up volume, pull up de

100 A syringe filled with diluted iodine contrast material was

101 anohybrid was further packed into a reusable syringe filter holder and applied as an adsorbent for so

102 mples, based on the capture of bacteria on a syringe filter, and the infection of targeted bacterial

103 ively coupled plasma mass spectrometry after syringe filtration (0.45 mum polyethersulfone membrane).

104 ge needle on a 3-way T-extension into a 3-mL syringe, followed by immediate infusion of absolute alco

105 counselling around timed condomless sex, or syringes for self-insemination.

106 itional Bacillus Calmette-Guerin needles and syringes for the administration of fIPV.

107 hase extraction by packed sorbent (in spinal syringe format) followed by HPLC-UV.

108 roof-of-concept of a novel integrated lab-in-syringe/gas-liquid separation (LIS/GLS) batch-flow syste

109 ed as non-inferior to that of the needle and syringe group if both the upper bound of each of the thr

110 jet injector group and 574 in the needle and syringe group).

111 Once the syringe has been filled, it is placed perpendicular to t

112 A 25 muL analytical glass syringe has been used for isoelectric focusing (IEF) uti

113 ellulose-treated paper wick assembled in the syringe hose.

114 de an alternative to conventional needle-and-syringe immunisation, and potentially offer improved imm

115 lonal antibody solutions stored in prefilled syringes in stressed stability studies.

116 to determine whether inclusion of stockpiled syringes in the measure improved sensitivity in discrimi

117 21 countries that had already introduced AD syringes in their national program.

118 or injectable delivery (RAPID) hydrogels are syringe-injectable and support cytocompatible encapsulat

119 Here we report novel syringe-injectable bioadhesive hydrogels with inherent a

120 We demonstrate several applications of syringe-injectable electronics as a general approach for

121 Such syringe-injectable hydrogels are highly desirable for mi

122 overcome this challenge by demonstrating the syringe injection (and subsequent unfolding) of sub-micr

123 Moreover, syringe injection enables the delivery of flexible elect

124 0, 4, and 8 weeks via single-dose needle and syringe injection in one deltoid or split-dose needle an

125 trategy for delivery via conventional needle-syringe injection of large preformed macroporous scaffol

126 PEDOT:PSS hydrogels form spontaneously after syringe injection of the PEDOT:PSS suspension into the d

127 s and splits bacterial samples upon a simple syringe injection step to initiate AST against all antib

128 electronics implanted into rodent brains by syringe injection that exhibit promising chronic tissue

129 versely, intradermal or intramuscular needle-syringe injection was ineffective, with only one partici

130 elivered by means of a hypodermic needle and syringe into muscle, in a process that bypasses the epid

131 tion of triamcinolone acetonide (TA) using a syringe is one of the most commonly used treatments for

132 A syringe is then used to actively transport the analyte a

133 mal dose by needle and syringe or disposable-syringe jet injector at a second visit.

134 s of IPV by needle and syringe or disposable-syringe jet injector compromises the immunity generated,

135 dose using needle and syringe or disposable-syringe jet injector.

136 ncluding intradermal adapters and disposable-syringe jet injectors, have also been developed and eval

137 expression of the genes encoding a molecular syringe known as a type III secretion system, leading to

138 secretion system - a multi-membrane spanning syringe-like apparatus - for their pathogenicity.

139 Many Gram-negative bacterial pathogens use a syringe-like apparatus called a type III secretion syste

140 f seven stacked MCE rings, and PqiB adopts a syringe-like architecture.

141 We investigated the syringe-like blood-feeding appendage, the stylet, and di

142 emorrhagic Escherichia coli (EHEC) engages a syringe-like machinery named type-III secretion system (

143 bacteria into epithelial cell cytosol via a syringe-like organelle known as the type III secretion s

144 During infection, the syringe-like T3SS injects cytotoxic proteins directly in

145 ium enteropathogenic Escherichia coli uses a syringe-like type III secretion system (T3SS) to inject

146 Pathogenic Gram-negative bacteria use syringe-like type III secretion systems (T3SS) to inject

147 rtantly, AuNPs-embedded paper-based lab-in-a-syringe (LIS) device is developed as a sensing strategy.

148 The flow-based analyzer features a lab-in-syringe (LIS) setup with an integrated stirring system,

149 A) and ferulic acid (FA) based on syringe-to-syringe magnetic solid-phase microextraction (SS-MSPME).

150 till collected using the 150-year-old needle/syringe method.

151 s performed with a metal sieve linked double syringe (MSLDS) system, which eliminated the need for a

152 ion of vaccines than injection by needle and syringe (N&S).

153 0, 4, 8) by Biojector(R) 2000 or needle and syringe (N/S) and boosted IM at week 24 with VRC-HIVADV0

154 edle-free jet injector (n=627) or needle and syringe (n=623).

155 lesh (ca. 10mg) was sampled directly using a syringe needle and placed in a glass insert for liquid e

156 acute loss of viability when ejected from a syringe needle, highlighting the protective capability o

157 A novel syringe needle-based sampling approach coupled with liqu

158 damage during ejection through a fine-gauge syringe needle.

159 ilm metallic glass (TFMG) for the coating of syringe needles and compares the results with those obta

160 separated from the aqueous phase within the syringe of an automated syringe pump.

161 The magnetic bar was placed inside the syringe of an automatic bidirectional syringe pump, enab

162 d 26.0 (0) mL for grade 4 FLA (1 mL equals 1 syringe of HA filler).

163 a towel (wipe group) or suction with a bulb syringe of the mouth and nostrils (suction group).

164 Seven unused syringes of bevacizumab prepared by the compounding phar

165 d a combination of interconnected valves and syringes operated by computer controlled pumps and ensur

166 or fractional intradermal dose by needle and syringe or disposable-syringe jet injector at a second v

167 ional intradermal doses of IPV by needle and syringe or disposable-syringe jet injector compromises t

168 s a full or fractional dose using needle and syringe or disposable-syringe jet injector.

169 tion in one deltoid or split-dose needle and syringe or needle-free injection with the Stratis device

170 1 intradermally or intramuscularly by needle-syringe or one of three needle-free devices.

171 iving ranibizumab in 1.0-mL BD polypropylene syringes or more recently glass prefilled syringes, 48.5

172 ypropylene syringes, BD 1.0-mL polycarbonate syringes, or controls (P < 0.001).

173 icantly greater than BD 1.0-mL polypropylene syringes (P = 0.012) and controls (P < 0.001).

174 distributes more than 1 million needles and syringes per year.

175 uroxime may be administered using pre-filled syringes (PFS), either prepared in hospital by reconstit

176 As the operator pushes the syringe plunger, the injector senses the loss-of-resista

177 se of this outbreak was contamination during syringe preparation by the compounding pharmacy.

178 halmitis after intravitreal bevacizumab from syringes prepared by a single compounding pharmacy.

179 is/oralis in vitreous specimens and 7 unused syringes prepared by the compounding pharmacy at the sam

180 bial contamination of bevacizumab-containing syringes prepared from the same vial of drug can be avoi

181 consisted of a transducer with a needleless syringe pressed over each flank.

182 Drug Reporting System study, PWIDs reported syringes procured and given away, total injections in th

183 ctice, allowing PWIDs greater flexibility in syringe procurement practices, promoting greater NSP cov

184 Needle and syringe program (NSP) coverage is commonly used to asses

185 CI: 0.06-0.67), and frequent users of needle/syringe program services had lower HIV incidence (0% in

186 e to evaluate the association between needle/syringe program use and HIV incidence.

187 past 12 months were recruited at needle and syringe programme sites using respondent-driven sampling

188 osure to services received at the needle and syringe programme sites.

189 one homelessness service, and one needle and syringe programme).

190 on interventions for PWID include needle and syringe programmes (NSP), opioid substitution therapy (O

191 prenorphine in five countries and needle and syringe programmes in three countries), with none of the

192 V prevention strategies including needle and syringe programmes, opioid agonist therapy, and antiretr

193 vention strategies include mobile needle and syringe programmes, pre-exposure prophylaxis, supervised

194 ransmission, such as expansion of needle and syringe programmes, upscaling of opioid agonist therapy,

195 st therapies and does not support needle and syringe programmes-with neither available in prisons-des

196 n therapy (OST) and high-coverage needle and syringe programs (HCNSP) cannot substantially reduce hep

197 cy: opioid agonist therapy (OAT), needle and syringe programs (NSPs), HIV testing and treatment (Test

198 preexisting interventions such as needle and syringe programs and opiate agonist therapy.

199 therapy and increased coverage of needle and syringe programs in North America.

200 essing community programs such as needle and syringe programs, treatment for substance use disorder,

201 investigated including syringe fill strokes, syringe pull up volume, pull up delay and volume in the

202 ct formation is suppressed even without slow syringe pump addition of the ethyl diazoacetate.

203 lus injector) was placed in-line between the syringe pump and microdialysis probe.

204 The poseidon syringe pump and microscope system is an open source alt

205 s infused as a postcolumn addition using the syringe pump at the time of elution of the analyte.

206 action (TIMFIE) sampler comprises a low-tech syringe pump driven by a rubber band and connected to a

207 With syringe pump injection, the detector is evaluated by mea

208 The syringe pump inside the TDS was devised in such a way th

209 A syringe pump is used to systematically investigate the e

210 ls, 3 mm wide by 1.5 mm deep, connected to a syringe pump through standard, threaded fittings.

211 luidics system can be operated with a single syringe pump to introduce drug compounds (which takes ap

212 A by the proper flow splitting design, and a syringe pump was employed to withdraw fluid through the

213 The setup was operated with a syringe pump, delivering reagents to the surface through

214 de the syringe of an automatic bidirectional syringe pump, enabling dispersion and subsequent magneti

215 The device only needs a syringe pump, thus removing the use of complex, expensiv

216 vely) templation method without the use of a syringe pump.

217 nd insulin were continuously administered by syringe pump.

218 ous phase within the syringe of an automated syringe pump.

219 m manually using a Teflon tube attached to a syringe pump; this method is simple enough it should be

220 re specialized engineering equipment such as syringe pumps and long time frames (hours) to develop a

221 using gravity-driven flow in the absence of syringe pumps and portable fluorescence imaging solution

222 (2-3 d), and they can be operated using two syringe pumps for lysed blood samples (7.5 ml in 12.5 mi

223 ing on-chip pumps for better portability and syringe pumps for precise fluid control, have been emplo

224 source approaches have been applied to build syringe pumps, centrifuges, and other laboratory equipme

225 n miniature off-the-shelf components such as syringe pumps, valves, and pressure controllers which co

226 ependent on complementary components such as syringe pumps.

227 a continuous flow system from reactor coils, syringes, pumps, in-line liquid-liquid separators, dryin

228 e is known about the factors associated with syringe purchase among injection drug users (IDUs).

229 ral, and spatial factors associated with OTC syringe purchase by IDUs.

230 Notably, the prevalence of OTC syringe purchase was 53% lower among African-American ID

231 upply were independently associated with OTC syringe purchases.

232 tor enhancing resistance against Pseudomonas syringe pv tomato DC3000.

233 aureus, and, for the first time, Pseudomonas syringe pv. actinidiae.

234 y against the bacterial pathogen Pseudomonas syringe pv. tomato (Pst) DC3000 in the salicylic acid (S

235 posable syringes and inadequately sterilized syringes resulted in 39% of all injections being unsafe,

236 e membraneless GLS located at the top of the syringe's valve in the upright position.

237 alifornia law allowed over-the-counter (OTC) syringe sales pending local authorization.

238 essential oil, avoiding difficulties in the syringe sample withdrawal process, prior to GC injection

239 f a logging system, which is equipped with a syringe sampler and sensors for the measurement of stand

240 The syringe samples drawn during continuous profiling were u

241 A-ICOS isotopic N2O laser analyzer through a syringe septum port.

242 ogram that colocates HCV management within a syringe service program in New York City.

243 rophylaxis (PrEP) for HIV prevention through syringe service programmes has the potential to save liv

244 NTERPRETATION: Naloxone distribution through syringe service programmes is cost-effective compared wi

245 ccess medication-assisted treatment (MAT) or syringe service programs (SSP) in urban San Francisco (e

246 ention types: behavioral-psychosocial (BPS), syringe service programs (SSP), opioid agonist therapy (

247 caling up direct-acting antiviral treatment, syringe service programs, and medication-assisted therap

248 m reduction approach, including expansion of syringe service programs, to address injection behaviors

249 rgency was declared on March 26, 2015, and a syringe-service program in Indiana was established for t

250 ith hepatitis C virus lived >10 miles from a syringe services program.

251 Syringe services programs (SSPs) are effective venues fo

252 deficiency virus prevention programs such as Syringe Services Programs (SSPs) could benefit from scre

253 Those with PSMI were less likely to use syringe services programs than those without PSMI.

254 This syringe-shaped 3.5-MDa macromolecular assembly spans bot

255 The bacterial injectisome is a syringe-shaped macromolecular nanomachine utilized by ma

256 95% CI, 1.01-2.08]; P = .042), and receptive syringe sharing (aHR, 1.43 [95% CI, 1.33-1.53]; P < .001

257 ) (aPR, 1.17 [95% CI, 1.03-1.33]), receptive syringe sharing (aPR, 1.37 [95% CI, 1.21-1.56]), sharing

258 HIV prevention and treatment indicators were syringe sharing (n=35) and prevalence of HIV infection a

259 A linear decrease in syringe sharing behavior was observed over time after HC

260 rt injecting more than once a day, receptive syringe sharing, sharing of other injection equipment, a

261 a, or was named by another case patient as a syringe-sharing or sexual partner.

262 The number of times a contact was named as a syringe-sharing partner by a case patient was significan

263 A fast method based on in-syringe solid phase extraction combined with dispersive

264 esults allow the (68)Ge activity of the mock syringe source to be expressed in terms of equivalent (1

265 esponse ratios for a (68)Ge solid epoxy mock syringe source used in activity calibrators as a long-li

266 published methodology, solution-filled mock syringe sources, identical in geometry to the solid (68)

267 Three-quarters of the sample reported syringe stockpiling, and stockpiling was positively asso

268 the type of drug injected, and the source of syringe supply were independently associated with OTC sy

269 -3.7%, allowing users of the commercial mock syringe surrogate source to calibrate their activity cal

270 reater in eyes using BD 0.3-mL polypropylene syringes than BD 1.0-mL polypropylene syringes, BD 1.0-m

271 apparatus (TTSA) is the molecular needle and syringe that form the energized conduit between the bact

272 on might offer an alternative to needles and syringes that avoids the issue of needle phobia and the

273 leaves by one of three methods: a needleless syringe, the agrodrench method or by pricking with a too

274 gative pathogens, comprises a trans-envelope syringe, the injectisome, with a cytoplasm-facing transl

275 ion of absolute alcohol from a separate 1-mL syringe through the other arm of the T-extension.

276 o a filter holder between filter papers on a syringe tip and used as an efficient adsorbent for the f

277 deformation, and could be injected through a syringe to adhere to the convex contour of a tissue surf

278 the type III secretion system as a molecular syringe to inject type III secreted effector (T3SE) prot

279 retion system which functions as a molecular syringe to translocate bacterial effector proteins direc

280 c acid (p-CA) and ferulic acid (FA) based on syringe-to-syringe magnetic solid-phase microextraction

281 g assisted DLLME were carried out inside the syringe void volume as a size-adaptable yet sealed mixin

282 re obtained for a sample volume equal to the syringe volume (5 mL).

283 A 25 gauge needle with 1 mL mounted syringe was filled with the tissue culture medium.

284 iated with bevacizumab prepared with insulin syringes was documented.

285 oplets in eyes using BD 1.0-mL polycarbonate syringes was significantly greater than BD 1.0-mL polypr

286 o the pharmacy that prepared the bevacizumab syringes was summarized.

287 es from patients and pre-filled saline flush syringes were closely related by PFGE, identifying conta

288 In the pilot study, left-over blood gas syringes were collected for further laboratory analysis.

289 Prefilled syringes were dispensed with the group allocation concea

290 The extracted water ends up in the syringe, where sample volume is accurately determined.

291 ions in the past month, and regular use of a syringe with a detachable needle were associated with HC

292 tered using the 0.1 mL HelmJect auto-disable syringe with a Helms intradermal adapter).

293 d by injecting the samples into them using a syringe with a needle or a pipet tip, and then sealing t

294 it was demonstrated that by flushing the EME-syringe with acidic wash buffer and reverting the applie

295 the IEF process and the coupling of the IEF syringe with electrospray ionization mass spectrometry (

296 d bevacizumab was delivered using 300 microL syringes with 5/16-inch, 30-gauge fixed needles.

297 b, 1.25 mg/0.05 mL, was delivered in insulin syringes with a 31-gauge needle.

298 bevacizumab and the BD 1.0-mL polycarbonate syringes with aflibercept cause a higher likelihood of s

299 The BD 0.3-mL polypropylene syringes with repackaged bevacizumab and the BD 1.0-mL p

300 Increased access to OTC syringes would potentially prevent blood-borne infectiou